COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Jaguar Health announced groundbreaking results from ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure, showing significant reduction of parenteral support (PS) and potential to save lives -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. receives $240,000 grant from FDA for Canalevia-CA1 study on chemotherapy-induced diarrhea in dogs. Focus on CID treatment effectiveness -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health announces submission of abstract detailing preliminary findings from clinical trial on a novel oral liquid formulation of crofelemer for SBS-IF patients, supporting the focus on reducing PS needs in intestinal failure patients
